4th Mar 2021 15:15
Press Release
Publication of Form 20-F
Hong Kong, Shanghai & Florham Park, NJ: Thursday, March 4, 2021: Hutchison China MediTech Limited ("HUTCHMED") (Nasdaq/AIM: HCM) today published the Form 20-F for the financial year ended December 31, 2020. This is available for viewing at http://www.rns-pdf.londonstockexchange.com/rns/2361R_1-2021-3-4.pdf and also on the website of the Company at www.hutch-med.com.
About HUTCHMED
HUTCHMED (Nasdaq/AIM: HCM) is an innovative, commercial-stage, biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has advanced ten cancer drug candidates from discovery into clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.hutch-med.com.
CONTACTS
Investor Enquiries |
|
Mark Lee, Senior Vice President | +852 2121 8200 |
Annie Cheng, Vice President | +1 (973) 567 3786 |
|
|
Media Enquiries |
|
Americas - Brad Miles, Solebury Trout | +1 (917) 570 7340 (Mobile) [email protected] |
Europe - Ben Atwell / Alex Shaw, FTI Consulting | +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)[email protected] |
Asia - Joseph Chi Lo / Zhou Yi, Brunswick | +852 9850 5033 (Mobile), [email protected] / +852 9783 6894 (Mobile), y[email protected] |
|
|
Nominated Advisor |
|
Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) Limited | +44 (20) 7886 2500 |
Related Shares:
Hutchmed